Skip to content
Review Open access

Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives

Aug 2026 · Eurasian Journal of Medicine and Oncology · pp. 026270318 · 0 citations

TL;DR

Modern CML management has transitioned from uniform kinase inhibition toward highly individualized survivorship, and Optimizing long-term quality of life relies on aligning tyrosine kinase inhibitor selection with patient-specific comorbidities, implementing response-adjusted dosing, and utilizing well-defined clinical parameters to safely evaluate candidates for treatment-free remission.

Abstract

Introduction: The therapeutic landscape of chronic myeloid leukemia (CML) represents a paradigm of precision oncology, evolving across multiple generations of targeted breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1 tyrosine kinase inhibitors. As survival approaches that of the general population, long-term care requires balancing drug efficacy with safety, sequencing optimization, and survivorship considerations. Objectives: This review aims to evaluate modern CML management strategies, including drug mechanisms, resistance mutations, toxicity profiles, treatment sequencing, and criteria for treatment discontinuation. Methods: Literature was retrieved up to June 2026 using databases indexing landmark phase I–III trials, European LeukemiaNet guidelines, and regulatory data. Evidence was synthesized thematically across adult chronic-phase CML management strategies to evaluate drug mechanisms, resistance mutations, organ-specific toxicities, and treatment discontinuation criteria. Results: First-generation imatinib provides a well-characterized safety profile but is associated with slower response kinetics. Second-generation agents (e.g., dasatinib, nilotinib, bosutinib) achieve deeper molecular responses but present distinct, non-overlapping toxicities—including pleural, vascular, metabolic, and gastrointestinal complications—and remain vulnerable to the T315I gatekeeper mutation. Third-generation ponatinib and the newly approved allosteric inhibitor asciminib, which specifically targets the ABL myristoyl pocket, provide effective options for salvage-resistant disease, though they necessitate proactive cardiovascular and metabolic risk mitigation. Standardized molecular monitoring remains essential to distinguish true resistance from nonadherence and to guide mutation-directed sequencing. Conclusion: Modern CML management has transitioned from uniform kinase inhibition toward highly individualized survivorship. Optimizing long-term quality of life relies on aligning tyrosine kinase inhibitor selection with patient-specific comorbidities, implementing response-adjusted dosing, and utilizing well-defined clinical parameters to safely evaluate candidates for treatment-free remission.

Read PDF

Similar papers

Review Open access Sep 2026

Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia.

Acute myeloid leukemia (AML) remains a major therapeutic challenge despite remarkable advances in genomic characterization. Although molecular profiling has transformed disease classification and risk stratification, treatment for most patients continues to rely on cytotoxic chemotherapy regimens developed more than 50...

S. Meshinchi, Franco Locatelli · 0 citations
Review Open access Oct 2026

Current and future therapies for acute myeloblastic leukemia

The role of intensive cytarabine plus anthracycline plus anthracycline-based regimens and venetoclax-based lower-intensity approaches are discussed, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML.

Jennifer Marvin-Peek, F. Ravandi · 0 citations
Open access Oct 2026

Paradigm Shifts in the Management of Chronic Myeloid Leukemia and Health Policy Challenges in the Era of High Cost Anticancer Drugs

Chronic myeloid leukemia (CML) therapy has evolved from survival-oriented management into the pursuit of a “functional cure,” characterized by treatment-free remission (TFR). Achieving a deep molecular response (DMR) is a critical prerequisite for TFR and recent clinical advances have introduced novel therapeutic optio...

Sang-Kyun Sohn · 0 citations
Open access Sep 2026

Genetic landscape of patients at diagnosis of chronic myeloid leukemia in the chronic phase: association with targeted therapy efficacy

Background. Despite advances in the treatment of chronic myeloid leukemia (CML), the problem of resistance to tyrosine kinase inhibitors (TKIs) remains unresolved. The role of additional gene mutations (besides BCR::ABL1) in resistance development is widely discussed. These mutations may influence the development of th...

O. Vinogradova, A. L. Neverova, A. R. Vekua et al. · 0 citations
Review Open access Sep 2026

Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine.

Since the discovery of cytotoxic agents in the mid-20th century, acute leukemia has consistently served as a model for oncology research. As the Human Genome Project and subsequent genomic profiling elucidated the landscape of somatic mutations and cytogenetic aberrations driving leukemogenesis, the development of mole...

Naoko Hosono, Naoko Ida, Takahiro Yamauchi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.